DiaMedica Therapeutics (DMAC) Receivables - Accured (2019 - 2026)

DiaMedica Therapeutics (DMAC) has reported Receivables - Accured for 8 consecutive years, with $236000.0 the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, Receivables - Accured rose 66.2% year-over-year to $236000.0; the trailing twelve-month figure through Jun 2026 stood at $236000.0 (up 66.2% YoY), and the FY2025 full-year result was $250000.0, up 6.38% from the prior year.
• Receivables - Accured fell to $236000.0 in Q2 2026 per DMAC's latest filing, from $285000.0 in the prior quarter.
• Across five years, Receivables - Accured topped out at $391000.0 in Q1 2024 and bottomed at $55000.0 in Q1 2023.
• Historically, Receivables - Accured has averaged $218111.1 across 5 years, with a median of $232000.0 in 2024.
• The sharpest annual moves came in 2022 and 2023: Receivables - Accured surged 877.78% in 2022, then plunged 66.87% in 2023.
• Over 5 years, Receivables - Accured stood at $80000.0 in 2022, then soared by 272.5% to $298000.0 in 2023, then dropped by 21.14% to $235000.0 in 2024, then rose by 6.38% to $250000.0 in 2025, then retreated by 5.6% to $236000.0 in 2026.
• According to Business Quant data, Receivables - Accured over the past three periods registered $236000.0, $285000.0, and $250000.0 for Q2 2026, Q1 2026, and Q4 2025 respectively.